经过CO(2) 激光转心肌激光再血管化后5年持续的心痛缓解
K A Horvath1, S F Aranki, L H Cohn
1Northwestern University Medical School, Chicago, Illinois, USA. khorvath@nmh.org
Circulation
|September 25, 2001
概括
透心肌激光重血管化 (TMR) 提供了对严重心肌痛的显著长期缓解,持续至少5年. 这种手术可以持续改善心肌痛等级和患者的生活质量.
科学领域:
- 心血管外科心血管外科
- 干预心脏病学 干预心脏病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 透心肌激光再血管 (TMR) 提供短期的胸痛缓解,但长期的疗效仍然不确定.
- 评估长期结果对于理解TMR的持续益处至关重要.
- 在TMR后7年内进行前性数据收集对于评估耐用性至关重要.
研究的目的:
- 为了评估心肌传动激光复血管化 (TMR) 对严重心痛的长期疗效.
- 评估心痛症状缓解的持久性超过手术后5年的时间.
- 用心痛类和西雅图心痛问卷 (SAQ) 评分来确认持续的改善.
主要方法:
- 78名患有严重,耐火性心肌痛的患者接受了CO2) 激光TMR.
- 患者被前性跟踪长达7年,通过胸痛类和SAQ评估胸痛症状.
- 手术前的特征包括高频率的不稳定性心肌痛,先前的心肌梗塞和先前的再血管化手术.
主要成果:
- 长期随访 (平均5年,最多7年) 显示,平均心痛类 (3.7至1.6) 显著改善.
- 痛的缓解持续,没有显著的变化类从1年到5年后TMR.
- 68%的患者经历了显著的长期胸痛缓解 (≥2级下降),SAQ得分比起基线改善了170%.
结论:
- 透心肌激光复血管 (TMR) 证明了在严重心痛中长期持续的疗效.
- 作为治疗失能性心痛的唯一疗法,TMR的好处持续至少5年.
- TMR可以显著而持久地缓解心痛的症状,改善患者的生活质量.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
884
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
Mitral Stenosis III: Medical Management
535
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535
Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Angina II: Classification
709
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
709
Angina III: Clinical Manifestations and Assessment
481
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
481
Angina IV: Management
493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493


